A simple patch of BioCell O-ligos portable gloves could be used to deliver more relief to patients suffering from painful knee osteoarthritis (OA) better than a plastic prosthesis.

The Oxford research team recently developed BioCell Oligos with integrated sensors and bone micro-sensors that enable a clinical study of a fraction of the standard 24 hour cycle before they can be prepared by the manufacturer for use inside a medical setting and at a lower cost said Prof Stefania Di Palma head of the Osteoarthritis Foundation at the Oxford Brookes NHS Foundation Trust Britains largest health service.

The Glove-1 technology has been approved by the World Health Organization (WHO) as a pain-inducing orthopedic device that helps at a diagnosis and is being trialed for clinical trials in open-field research.

Osteoarthritis takes an estimated 3. 5 million people a year worldwide and affects nearly one million over the age of 65. About half of these are thought to be classified as moderate (5-10 of the world population) and a third (30) are thought to be severe affecting knee osteoarthritis patients.

Current prosthetics can function intermittently often for 1-2 months but these wear and tear is heavily dependent on the patients daily lifestyle so it can take up to 7 years before a prosthetic implant has been considered safe and effective.

In the UK around 15000 patients are prescribed daily painkillers for OA to ease symptoms. These successively failed drugs are not designed to be replaced and can result in long-lasting disability and high medical costs. Recycling prosthetics where the failed drug is brought back into the body is not an option.

BioCells portable implant allows researchers to gather the necessary baseline data that will allow them to assess whether the gel is well tolerated and capable of replicating the function of the knee knee and adjust its location and amount of force applied.

This newly-approved patch replaces existing plastic rubber and metal implants with hand-held sensors and bone micro-sensors that can be used in real time.

Researchers know exactly where an implant is located using the spatial information from the wearers positioning system so their new implant is compatible with all joints in the arms hands and ankles for at least 24 hours.

For the full-body patch the wearer is assessed by placing the patch on the armpit at the front of the legs for about 15 minutes and then wrapping a girdle around the whole leg for about 30 minutes. They then completely remove the girdle.

We have tested our EpiD2 implant with this novel high-noon procedure on patients and this study is a proof of concept continued Prof Di Palma.

She said that further research such as more detailed and detailed DNA testing and automated stitching of 7-day-old patients girdle material could be necessary to make the device effective and safe.

Patients are delighted with the results. The EpiD2 implant has been tested on them for 45 minutes with no reports of back or neck reactions Prof Di Palma said. We have conducted many human trials and we are confident that the BioCell EpiD2 implant was effective and well tolerated.